Loading
A phase 1/2 trial of AZD3470 and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2026-08-27: recruiting. Enrollment is planned at 334 participants. Primary completion is estimated at 2028-12-04. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: AZD3470, Datopotamab deruxtecan. Registered primary measures: All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents; Module 1: Incidence of dose-limiting toxicities (DLT); Module 2: Progression Free Survival assessed by the Investigator according to RECIST v1.1.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Datopotamab deruxtecan, TROP2, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Datopotamab deruxtecan, TROP2, AstraZeneca and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Datopotamab deruxtecan, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/